|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 16.11 USD | +0.75% |
|
-7.09% | -24.93% |
| Apr. 09 | UBS Adjusts Denali Therapeutics Price Target to $32 From $70, Maintains Buy Rating | MT |
| Apr. 03 | Denali Therapeutics Insider Sold Shares Worth $1,896,250, According to a Recent SEC Filing | MT |
Denali Therapeutics Inc. reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported revenue was USD 35.14 million compared to USD 42.14 million a year ago. Net loss was USD 109.78 million compared to USD 65.22 million a year ago.
Basic loss per share from continuing operations was USD 0.8 compared to USD 0.53 a year ago. Diluted loss per share from continuing operations was USD 0.8 compared to USD 0.53 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -24.93% | 2.3B | |
| -0.49% | 105B | |
| +3.31% | 97.5B | |
| +2.97% | 22.19B | |
| -16.16% | 21.33B | |
| -7.31% | 18.68B | |
| -41.41% | 16.6B | |
| -22.87% | 14.52B | |
| +6.32% | 14.09B | |
| +21.46% | 10.99B |
DENALI THERAPEUTICS INC. 
